Antidepressant Tx Increases Subsequent Mania/Bipolar Risk

This article originally appeared here.
Share this content:
Antidepressant Tx Increases Subsequent Mania/Bipolar Risk
Antidepressant Tx Increases Subsequent Mania/Bipolar Risk

WEDNESDAY, Dec. 16, 2015 (HealthDay News) -- For patients with unipolar depression, the risk of subsequent mania/bipolar disorder is increased in association with antidepressant treatment, according to a study published online Dec. 14 in BMJ Open.

Rashmi Patel, B.M., B.Ch., from King's College London, and colleagues examined the correlation between antidepressant therapy and later onset of mania/bipolar disorder in a retrospective cohort study. Data were reviewed for 21,012 adults presenting to the South London and Maudsley National Health Service Trust with unipolar depression between April 1, 2006, and March 31, 2013.

The researchers found that the overall incidence rate of mania/bipolar disorder was 10.9/1,000 person-years. The peak incidence of mania/bipolar disorder was observed in patients aged 26 to 35 years (12.3 per 1,000 person-years). There was a correlation between prior antidepressant treatment with increased incidence of mania/bipolar disorder, varying from 13.1 to 19.1 per 1,000 person-years. Significant correlations were seen for selective serotonin reuptake inhibitors and venlafaxine (hazard ratios, 1.34 and 1.35, respectively).

"In people with unipolar depression, antidepressant treatment is associated with an increased risk of subsequent mania/bipolar disorder," the authors write. "These findings highlight the importance of considering risk factors for mania when treating people with depression."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »